Oncology Ny · Oct 2014
read more…
no abstract available
Pubmed Copy Citation
Add institutional full text...
'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
Expert Rev Anticancer Ther. 2014 Nov 1; 14 (11): 1253-6.
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
BJU Int. 2012 Oct 1;110(8):1149-55.
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Lancet Oncol. 2012 Jun 1; 13 (6): 573-4.
hide…
We guarantee your privacy. Your email address will not be shared.
Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.
Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.
Includes a free 21 day trial of metajournal premium
We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.